Skip to main content
SpringerLink
Log in

mGlu2/3 Receptor Antagonists as Rapid-Acting Antidepressants

  • Chapter
  • First Online:
New Rapid-acting Antidepressants

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

Abstract

Since the discovery of the robust and rapid-acting antidepressant effects of ketamine in patients with treatment-resistant depression, the glutamatergic system has gained significant attention as an attractive target for the development of novel antidepressants. As part of the glutamatergic system, metabotropic glutamate (mGlu) receptors are of interest because mGlu receptors play regulatory roles in glutamate transmission. Accumulating evidence has suggested that a blockade of group II mGlu receptors, consisting of mGlu2 and mGlu3 receptors, is an effective approach to exert antidepressant actions. Indeed, animal studies using selective mGlu2/3 receptor antagonists have revealed that mGlu2/3 receptor antagonists have antidepressant profiles similar to those of ketamine: rapid-acting antidepressant effects and efficacy in models refractory to current medications. Moreover, mGlu2/3 receptor antagonists do not show ketamine-like side effects such as psychotomimetic-like behaviors and abuse potential. Therefore, mGlu2/3 receptor antagonists can function as novel antidepressants that may be devoid of ketamine-like side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2013) Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65:29–38

    Article  CAS  PubMed  Google Scholar 

  • Aronica E, Gorter JA, Rozemuller AJ, Yankaya B, Troost D (2005) Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1beta-stimulated release of IL-6 in cultured human astrocytes. Neuroscience 130:927–933

    Article  CAS  PubMed  Google Scholar 

  • Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354

    Article  CAS  PubMed  Google Scholar 

  • Chaki S (2010) Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol 639:59–66

    Article  CAS  PubMed  Google Scholar 

  • Chaki S (2017a) Beyond ketamine: new approaches to the development of safer antidepressants. Curr Neuropharmacol 15:963–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chaki S (2017b) mGlu2/3 receptor antagonists as novel antidepressants. Trends Pharmacol Sci 38:569–580

    Article  CAS  PubMed  Google Scholar 

  • Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A (2013) mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 66:40–52

    Article  CAS  PubMed  Google Scholar 

  • Chaki S, Koike H, Fukumoto K (2019) Targeting of metabotropic glutamate receptors for the development of novel antidepressants. Chronic Stress 3:1–13

    Article  Google Scholar 

  • Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457–467

    Article  CAS  PubMed  Google Scholar 

  • Chang L, Zhang K, Pu Y, Qu Y, Wang SM, Xiong Z, Shirayama Y, Hashimoto K (2019) Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-019-01012-1

  • Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237

    Article  CAS  PubMed  Google Scholar 

  • Dong C, Zhang JC, Yao W, Ren Q, Ma M, Yang C, Chaki S, Hashimoto K (2017) Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int J Neuropsychopharmacol 20:228–236

    CAS  PubMed  Google Scholar 

  • Drevets WC, Zarate CA Jr, Furey ML (2013) Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 73:1156–1163

    Article  CAS  PubMed  Google Scholar 

  • Duman CH, Duman RS (2015) Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci Lett 601:20–29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33:1603–1610

    Article  CAS  PubMed  Google Scholar 

  • Durand D, Carniglia L, Caruso C, Lasaga M (2013) mGlu3 receptor and astrocytes: partners in neuroprotection. Neuropharmacology 66:1–11

    Article  CAS  PubMed  Google Scholar 

  • Dwyer JM, Lepack AE, Duman RS (2012) mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol 15:429–434

    Article  CAS  PubMed  Google Scholar 

  • Dwyer JM, Lepack AE, Duman RS (2013) mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 1:15

    Article  PubMed  PubMed Central  Google Scholar 

  • Engers JL, Bollinger KA, Weiner RL, Rodriguez AL, Long MF, Breiner MM, Chang S, Bollinger SR, Bubser M, Jones CK, Morrison RD, Bridges TM, Blobaum AL, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW (2017) Design and synthesis of N-Aryl phenoxyethoxy pyridinones as highly selective and CNS penetrant mGlu3 NAMs. ACS Med Chem Lett 8:925–930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, Blobaum AL, Chang S, Venable DF, Loch MT, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2015) Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents. J Med Chem 58:7485–7500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, Wafford KA, Seidel WF, Edgar DM, Quets AT, Felder CC, Wang X, Heinz BA, Nikolayev A, Kuo MS, Mayhugh D, Khilevich A, Zhang D, Ebert PJ, Eckstein JA, Ackermann BL, Swanson SP, Catlow JT, Dean RA, Jackson K, Tauscher-Wisniewski S, Marek GJ, Schkeryantz JM, Svensson KA (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336:165–177

    Article  CAS  PubMed  Google Scholar 

  • Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PB, Hasler G, Stockmeier CA, Iyo AH, Karolewicz B (2010) Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 34:279–283

    Article  CAS  Google Scholar 

  • Fukumoto K, Iijima M, Chaki S (2014) Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology 231:2291–2298

    Article  CAS  PubMed  Google Scholar 

  • Fukumoto K, Iijima M, Chaki S (2016) The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41:1046–1056

    Article  CAS  PubMed  Google Scholar 

  • Fukumoto K, Iijima M, Funakoshi T, Chaki S (2018a) 5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2/3 receptor antagonist in mice. Neuropharmacology 137:96–103

    Article  CAS  PubMed  Google Scholar 

  • Fukumoto K, Iijima M, Funakoshi T, Chaki S (2018b) Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol 21:371–381

    Article  CAS  PubMed  Google Scholar 

  • Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361:9–16

    Article  CAS  PubMed  Google Scholar 

  • Gasull-Camós J, Martínez-Torres S, Tarrés-Gatius M, Ozaita A, Artigas F, Castañé A (2018) Serotonergic mechanisms involved in antidepressant-like responses evoked by GLT-1 blockade in rat infralimbic cortex. Neuropharmacology 139:41–51

    Article  PubMed  CAS  Google Scholar 

  • Gasull-Camós J, Tarrés-Gatius M, Artigas F, Castañé A (2017) Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats. Transl Psychiatry 7:e1038. https://doi.org/10.1038/tp.2017.7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA (2009) Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 166:812–820

    Article  PubMed  PubMed Central  Google Scholar 

  • Gleason SD, Li X, Smith IA, Ephlin JD, Wang XS, Heinz BA, Carter JH, Baez M, Yu J, Bender DM, Witkin JM (2013) mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice. CNS Neurol Disord Drug Targets 12:554–566

    Article  CAS  PubMed  Google Scholar 

  • Goeldner C, Ballard TM, Knoflach F, Wichmann J, Gatti S, Umbricht D (2013) Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 64:337–346

    Article  CAS  PubMed  Google Scholar 

  • Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS (2019) Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun 10:223. https://doi.org/10.1038/s41467-018-08168-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Highland JN, Zanos P, Georgiou P, Gould TD (2019) Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology. https://doi.org/10.1038/s41386-019-0380-1

  • Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, Mutel V (2004) Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907–917

    Article  CAS  PubMed  Google Scholar 

  • Hiyoshi T, Marumo T, Hikichi H, Tomishima Y, Urabe H, Tamita T, Iida I, Yasuhara A, Karasawa J, Chaki S (2014) Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor. J Pharmacol Exp Ther 351:642–653

    Article  PubMed  CAS  Google Scholar 

  • Iijima M, Ito A, Kurosu S, Chaki S (2010) Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 1359:75–80

    Article  CAS  PubMed  Google Scholar 

  • Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, Karolewicz B (2011) The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 35:1774–1779

    Article  CAS  Google Scholar 

  • Karasawa J, Kotani M, Kambe D, Chaki S (2010) AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell. Neurochem Int 57:615–619

    Article  CAS  PubMed  Google Scholar 

  • Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042:92–98

    Article  CAS  PubMed  Google Scholar 

  • Kawasaki T, Ago Y, Yano K, Araki R, Washida Y, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2011) Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology 60:397–404

    Article  CAS  PubMed  Google Scholar 

  • Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (2005) Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 378:131–134

    Article  CAS  PubMed  Google Scholar 

  • Kinon BJ, Millen BA, Zhang L, McKinzie DL (2015) Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 78:754–762

    Article  CAS  PubMed  Google Scholar 

  • Koike H, Iijima M, Chaki S (2011a) Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 61:1419–1423

    Article  CAS  PubMed  Google Scholar 

  • Koike H, Iijima M, Chaki S (2011b) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107–111

    Article  CAS  PubMed  Google Scholar 

  • Koike H, Iijima M, Chaki S (2013b) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav 107:20–23

    Article  CAS  PubMed  Google Scholar 

  • Koike H, Fukumoto K, Iijima M, Chaki S (2013a) Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 238:48–52

    Article  CAS  PubMed  Google Scholar 

  • Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lepack AE, Bang E, Lee B, Dwyer JM, Duman RS (2016) Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Neuropharmacology 111:242–252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754–761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Matrisciano F, Caruso A, Orlando R, Marchiafava M, Bruno V, Battaglia G, Gruber SH, Melchiorri D, Tatarelli R, Girardi P, Mathè AA, Nicoletti F (2008) Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 55:525–531

    Article  CAS  PubMed  Google Scholar 

  • Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, Witztum J, Shaver DC, Rosenthal DL, Alway EJ, Lopez K, Meng Y, Nellissen L, Grosenick L, Milner TA, Deisseroth K, Bito H, Kasai H, Liston C (2019) Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364. pii: eaat8078. https://doi.org/10.1126/science.aat8078

  • Monteggia LM, Zarate C Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139–143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, Nakamura M, Chaki S (2004) Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem 47:4570–4587

    Article  CAS  PubMed  Google Scholar 

  • Nasca C, Bigio B, Zelli D, Nicoletti F, McEwen BS (2015) Mind the gap: glucocorticoids modulate hippocampal glutamate tone underlying individual differences in stress susceptibility. Mol Psychiatry 20:755–763

    Article  CAS  PubMed  Google Scholar 

  • Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F (2013) L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 110:4804–4809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Neale SA, Salt TE (2006) Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor. J Physiol 577:659–669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Neki A, Ohishi H, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N (1996) Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci Lett 202:197–200

    Article  CAS  PubMed  Google Scholar 

  • Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009–1018

    Article  CAS  PubMed  Google Scholar 

  • Ohishi H, Shigemoto R, Nakanishi S, Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 335:252–266

    Article  CAS  PubMed  Google Scholar 

  • Pilc A, Chaki S, Nowak G, Witkin JM (2008) Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 75:997–1006

    Article  CAS  PubMed  Google Scholar 

  • Podkowa K, Pochwat B, BraÅ„ski P, Pilc A, PaÅ‚ucha-Poniewiera A (2016a) Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology 233:2901–2914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Podkowa K, Podkowa A, SaÅ‚at K, Lenda T, Pilc A, PaÅ‚ucha-Poniewiera A (2016b) Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology 111:169–179

    Article  CAS  PubMed  Google Scholar 

  • Schoepp DD, Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14(1):13–20

    Article  CAS  PubMed  Google Scholar 

  • Shimazaki T, Iijima M, Chaki S (2004) Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 501:121–125

    Article  CAS  PubMed  Google Scholar 

  • Shimazaki T, Kaku A, Chaki S (2007) Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol 575:94–97

    Article  CAS  PubMed  Google Scholar 

  • Swanson CJ, Perry KW, Schoepp DD (2004) The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. J Neurochem 88:194–202

    Article  CAS  PubMed  Google Scholar 

  • Tanabe Y, Nomura A, Masu M, Shigemoto R, Mizuno N, Nakanishi S (1993) Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 13:1372–1378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Umbricht D et al (2015) Results of a double-blind placebo-controlled study of the antidepressant effects of the mGLU2 negative allosteric modulator RG1578. Eur Neuropsychopharmacol 25:S447

    Article  Google Scholar 

  • Witkin JM, Mitchell SN, Wafford KA, Carter G, Gilmour G, Li J, Eastwood BJ, Overshiner C, Li X, Rorick-Kehn L, Rasmussen K, Anderson WH, Nikolayev A, Tolstikov VV, Kuo MS, Catlow JT, Li R, Smith SC, Mitch CH, Ornstein PL, Swanson S, Monn JA (2017a) Comparative effects of LY3020371, a potent and selective metabotropic glutamate (mGlu) 2/3 receptor antagonist, and ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist in rodents: evidence supporting the use of mGlu2/3 antagonists, for the treatment of depression. J Pharmacol Exp Ther 361:68–86

    Article  CAS  PubMed  Google Scholar 

  • Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM (2016) The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits. J Pharmacol Exp Ther 358:71–82

    Article  CAS  PubMed  Google Scholar 

  • Witkin JM, Monn JA, Li J, Johnson B, McKinzie DL, Wang XS, Heinz BA, Li R, Ornstein PL, Smith SC, Mitch CH, Calligaro DO, Swanson S, Allen D, Phillips K, Gilmour G (2017b) Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects. Pharmacol Biochem Behav 155:43–55

    Article  CAS  PubMed  Google Scholar 

  • Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, Monn JA, Schoepp DD, Marek GJ (2013) CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography. Neuropharmacology 66:89–98

    Article  CAS  PubMed  Google Scholar 

  • Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632. https://doi.org/10.1038/tp.2015.136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yoshimizu T, Shimazaki T, Ito A, Chaki S (2006) An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 186:587–593

    Article  CAS  PubMed  Google Scholar 

  • Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD (2019) (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci U S A 116:6441–6450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang K, Dong C, Fujita Y, Fujita A, Hashimoto K (2018) 5-Hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol 21:157–163

    Article  CAS  PubMed  Google Scholar 

  • Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Saitama, Japan

    Shigeyuki Chaki

Authors
  1. Shigeyuki Chaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeyuki Chaki .

Editor information

Editors and Affiliations

  1. Center for Forensic Mental Health, Chiba University, Chiba, Japan

    Kenji Hashimoto

  2. Service de Neurologie, CHU-Charleroi, Bruxelles, Belgium

    Mario Manto

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chaki, S. (2021). mGlu2/3 Receptor Antagonists as Rapid-Acting Antidepressants. In: Hashimoto, K., Manto, M. (eds) New Rapid-acting Antidepressants. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-030-79790-4_7

Download citation

Publish with us

Policies and ethics

Search

Navigation